Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Takes Rare Diseases Option from Prosensa

This article was originally published in Start Up

Executive Summary

GlaxoSmithKline's tie-up with Dutch biotech Prosensa around four RNA-modulating therapeutics for Duchenne Muscular Dystrophy, a rare genetic disorder, provides recent evidence that even the largest Big Pharma are embracing the most niche of specialist disease indications.

You may also be interested in...



Rare Form: GSK, NEA Back Orphan Disease Venture Fund

A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.

Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug

The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.

Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug

The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091694

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel